Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
04:00pm, Wednesday, 19'th Mar 2025
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compan
Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical comp
Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage bioph
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
04:00pm, Monday, 10'th Feb 2025
Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the
Daix (France), New York City (New York, United States), January 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
04:00pm, Friday, 24'th Jan 2025
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
04:00pm, Tuesday, 17'th Dec 2024
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the
Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical comp
Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024
04:00pm, Thursday, 12'th Dec 2024
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the
Inventiva reports 2024 Third Quarter Financial Information¹
04:00pm, Thursday, 21'st Nov 2024
Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
04:00pm, Wednesday, 20'th Nov 2024
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of or
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
08:30am, Monday, 18'th Nov 2024
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform.
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of or
Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on t
